Roche Holding AG
Swiss ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Roche Holding AG is a Swiss multinational healthcare company that develops, manufactures and markets pharmaceuticals and diagnostics worldwide. Founded in 1896 and headquartered in Basel, Switzerland, the company operates through two primary segments: Pharmaceuticals, which focuses on prescription medicines in oncology, immunology, infectious diseases, neuroscience, ophthalmology, haematology, inflammatory and respiratory diseases, cardiovascular and metabolic disorders; and Diagnostics, which provides in vitro diagnostic equipment, reagents and solutions including professional diagnostics, molecular diagnostics, diabetes care, tissue diagnostics and applied science products targeting physicians, hospitals, clinics, consumers and research settings in academia and industry. Roche maintains a global presence with significant operations across Europe, North America, Asia-Pacific and other regions, and holds majority ownership in Chugai Pharmaceutical in Japan while fully owning Genentech in the United States. In recent developments, Roche entered a definitive merger agreement in September 2025 to acquire 89bio for up to $3.5 billion to bolster its cardiovascular, renal and metabolic diseases portfolio with pegozafermin, a phase 3 FGF21 analog for moderate to severe metabolic dysfunction-associated steatohepatitis (MASH); received European Commission conditional approval for subcutaneous Lunsumio in relapsed/refractory follicular lymphoma; reported positive phase III results for fenebrutinib in multiple sclerosis; and announced a clinical trial collaboration with KaliVir Immunotherapeutics for oncology immunotherapies, alongside prior acquisitions such as Carmot Therapeutics in 2024, Televant Holdings and Good Therapeutics programs.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
Assemblée générale annuelle 2026 de Roche
Roche Generalversammlung 2026
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
European Commission approves Roche's Gazyva/Gazyvaro for adults with active lupus nephritis
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025